# Prelude Therapeutics Announces Strategic Business Update
Canonical URL: https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-strategic-business-update
Ticker: PRLD
Company: Prelude Therapeutics
Source: Prelude Therapeutics
Published: 2025-11-04 12:05 EST
Original Source URL: https://investors.preludetx.com
## Summary

Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a

## Article Body
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a
## Recent Company News
- 2026-05-12 11:01 EST — [Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Prelude Therapeutics
- 2026-04-20 10:30 EST — [Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering) — Source: Prelude Therapeutics
- 2026-04-20 10:00 EST — [Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026) — Source: Prelude Therapeutics
- 2026-04-15 11:30 EST — [Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer) — Source: Prelude Therapeutics
- 2026-03-17 20:31 EST — [Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-acceptance-of-preclinical-abstract-for-prt13722-a-first-in-class-oral-kat6a-selective-degrader-at-the-2026-aacr-annual-meeting) — Source: Prelude Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)